Paris (France), April 14th 2022.Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.The Crohn’s & Colitis Foundation is one of world’s largest and most influential non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis.
